Head-to-head · WeighScore
Blue Sky MD vs Bon Health
The verdict
Bon Health takes it — 69.7/100 to 67.7/100, but only just.
Bon Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Bon Health is a physician-led GLP-1 weight-loss telehealth service selling compounded semaglutide and tirzepatide on commitment tiers. Blue Sky MD is close behind and may still be the better fit — see the factor split below.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Blue Sky MD | Bon Health |
|---|---|---|
| WeighScore | 67.7/100 | 69.7/100 |
| Grade | C | C |
| Scorecard rank | #157 | #113 |
| Semaglutide | $160/mo (starting dose, compounded) | $120/mo (12-month plan, compounded) |
| Tirzepatide | $240/mo (starting dose, compounded) | $170/mo (12-month plan, compounded) |
| Coverage | 1 state | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #157 · C
Strengths
- LegitScript certified and physician-led since 2008; one of the most established GLP-1 practices in the Southeast
- Compounded semaglutide from $40/week (~$160/month) and tirzepatide from $60/week (~$240/month) — well below brand-name cost
- Comprehensive program includes 1-on-1 wellness coaching, nutrition plans, hormone analysis, and a proprietary mobile app
- Medication shipped directly to patients’ homes within 3–5 business days; telehealth visits available
- Insurance accepted in many cases; affordable self-pay options for uninsured patients
Where it loses points
- Geographic reach unclear — physical clinics in NC only; telehealth states beyond NC unconfirmed despite 'from virtually anywhere' claim
- Pricing quoted per-week ($40 sema / $60 tirz) rather than per-month; higher-dose pricing not disclosed
- Must enroll in full medical weight-loss program to access GLP-1 medications — medication-only Rx not offered
- No explicit lab testing protocol published; online FAQ does not confirm labs are included
- Small regional provider vs. national platforms; limited provider footprint outside North Carolina
Graded #113 · C
Strengths
- Transparent commitment-tier pricing from $170/mo (annual) for compounded semaglutide and tirzepatide; $0 membership fee, cancel anytime
- Physician-led: comprehensive medical review and physician-titrated dosing, not a 2-minute quiz
- 24/7 physician support included free with your order; 1-3 day rapid dispatch
- Licensed in all 50 states; uses 503A & 503B compounding pharmacies; brand-name Wegovy/Ozempic/Zepbound/Mounjaro also offered
Where it loses points
- The advertised rates need a full year paid up front; billed monthly, semaglutide is $230 and the annual figure nearly doubles
- The brand-name pages are marketing, not products — every Wegovy, Ozempic, Zepbound and Mounjaro CTA reads 'Coming Soon' and points back to the compounded version
- Coverage is not published: a badge claims all 50 states while the weight-loss page says availability varies by state
- The terms page returns a 404, so the refund mechanics behind the prepaid 3-, 6- and 12-month tiers cannot be read
- Compounded semaglutide and tirzepatide are not FDA-approved finished products
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.